Literature DB >> 1617673

Distribution of the glucose transporters in human brain tumors.

T Nishioka1, Y Oda, Y Seino, T Yamamoto, N Inagaki, H Yano, H Imura, R Shigemoto, H Kikuchi.   

Abstract

In the present study, we have investigated the expression of both the erythrocyte-type (GLUT1) and the brain-type (GLUT3) glucose transporter isoforms in primary human brain tumors. In situ hybridization made it possible to localize and semiquantify both GLUT1 and GLUT3 mRNAs of individual cells in all 18 samples examined. More signals for GLUT3 mRNA than for GLUT1 mRNA were found over astrocytoma cells, while the reverse was the case in all 6 meningiomas. In astrocytomas, for both mRNAs, the density of silver grains over tumor cells was well correlated with the malignancy of the cells. This correlation was, as was also confirmed by Northern blot analysis, more marked with GLUT3 mRNA than with GLUT1 mRNA. In 2 of 5 anaplastic astrocytomas and in all 3 glioblastomas, numerous tumor cells with large amounts of both mRNAs tended to surround the perivascular regions. "Tumor vessels" with endothelial proliferation, an almost pathognomonic feature of glioblastomas, expressed much GLUT3 mRNA but no significant GLUT1 mRNA, while a single- or a few-layered capillary endothelium expressed much GLUT1 mRNA. The distribution of both mRNAs was in good accordance with that of both proteins. Our results suggest that the expression of both glucose transporter isoforms may contribute to the maintenance of human brain tumors and that the expression of the GLUT3 isoform may be closely related to the malignant change of astrocytomas and particularly related to the aberrant neovascularization which accompanies glioblastomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617673

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  [Preoperative imaging as the basis for image-guided neurosurgery].

Authors:  D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

Review 2.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 3.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  Immunohistochemical expression of glucose transporter-1 in human penile proliferative lesions.

Authors:  N Moriyama; S Kurimoto; K Kawabe; K Takata; H Hirano
Journal:  Histochem J       Date:  1997-04

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 6.  Oncogene-directed alterations in cancer cell metabolism.

Authors:  Arvindhan Nagarajan; Parmanand Malvi; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2016-06-27

7.  Thrombin-induced translocation of GLUT3 glucose transporters in human platelets.

Authors:  L R Sorbara; T M Davies-Hill; E M Koehler-Stec; S J Vannucci; M K Horne; I A Simpson
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

8.  Gene expression of GLUT3 glucose transporter regulated by glucose in vivo in mouse brain and in vitro in neuronal cell cultures from rat embryos.

Authors:  S Nagamatsu; H Sawa; N Inoue; Y Nakamichi; H Takeshima; T Hoshino
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

9.  Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains.

Authors:  M Maruno; T Yoshimine; T Isaka; R Kuroda; H Ishii; T Hayakawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.